

Substitute for FORM 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) Sheet 1 of 1	Complete if Known	
	Application Number:	10/813,760
	Filing Date:	March 31, 2004
	First Named Inventor:	Joel Bernstein
	Group Art Unit:	1614
	Confirmation Number:	5267
	Examiner Name:	Kwon, Brian Yong S.
	Attorney Docket Number:	41959-102739

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Office	Foreign Patent Document		Name of Patentee or Applicant	Date of Publication	Translation	
			Application or Patent Number	Kind Code			Yes	No**

OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation			
			Yes	No**		
	CC	Hoekstra et al., "Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis," <i>Annals. of Rheumatic Diseases, British Medical Association, London.</i> , 62 (5) 423-426 (2003).				

CHDS01 AOM 503828v1

EXAMINER		DATE CONSIDERED	
----------	--	-----------------	--

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).